Policy changes are needed to ensure that Cooperative Research and Development Agreements and patent applications filed by the US National Institutes of Health are aligned with the interests of the American public.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sagal, M. W., Slowinski, G., Freese, K. & Ferguson, S. LES Nouv. 44, 41–48 (2009).
Ansher, S. S. & Scharf, R. Ann. NY Acad. Sci. 949, 333–340 (2001).
Ivy, S. P. Oncology (Williston Park) 14 (Suppl. 11), 27–29 (2000).
Teicher, B. A. & Anderson, K. C. Clin. Cancer Res. 21, 939–941 (2015).
Sanchez-Serrano, I. Discov. Med 5, 527–533 (2005).
US District Court. University of Kansas Center for Research, Inc. vs. United States of America, represented by the Department of Health and Human Services, by and through its agents the National Institutes of Health and the National Cancer Institute (2008); https://www.patentdocs.org/files/u_ks_v_us.pdf
Allen, S. The Velcade story. The Boston Globe http://archive.boston.com/business/healthcare/articles/2007/05/06/the_velcade_story/ (6 May 2007).
US District Court. University of Kansas Center for Research, Inc. vs. United States of America, represented by the Department of Health and Human Services, by and through its agents the National Institutes of Health and the National Cancer Institute. (2009); https://www.govinfo.gov/content/pkg/USCOURTS-ksd-2_08-cv-02565/pdf/USCOURTS-ksd-2_08-cv-02565-0.pdf
US Securities and Exchange Commission. Form 10-K (2004); https://www.sec.gov/Archives/edgar/data/1002637/000104746904007316/a2130167z10-k.htm#cm1241_item_5._market_for_the_registr__ite04803
Takeda to acquire Millennium for US$25.00 per share in an all cash tender offer valued at $8.8 billion. Fierce Biotech (10 April 2008); https://www.fiercebiotech.com/biotech/takeda-to-acquire-millennium-for-us-25-00-per-share-an-all-cash-tender-offer-valued-at-8-8
US Securities and Exchange Commission. Form 20-F (2018); https://assets-dam.takeda.com/raw/upload/v1662727578/legacy-dotcom/siteassets/system/investors/report/sec-filings/20-F_2018-12-17.pdf
US Government Accountability Office. NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property (2020); https://www.gao.gov/assets/720/710328.pdf
Shah, P., Vaughan, G. & Ledley, F. D. PLoS One 18, e0283887 (2023).
SEER. Myeloma - Cancer Stat Facts (accessed 19 May 2023); https://seer.cancer.gov/statfacts/html/mulmy.html
Fujisawa, M., Suehara, Y., Fukumoto, K., Takeuchi, M. & Matsue, K. Ann. Hematol. 95, 63–72 (2016).
Multiple Myeloma Research Foundation. Generic versions of Revlimid and Velcade now available for patients with multiple myeloma. MMRF Blogs (10 June 2022); https://themmrf.org/wp-content/uploads/2023/07/Treatment-Overview_patient-toolkit.pdf
NIH Office of Technology Transfer. Model PHS CRADA for Extramural-PHS Clinical Research (2018); https://www.ott.nih.gov/sites/default/files/documents/docs/Model-PHS-ECT-CRADA-rev2018.docx
NIH Office of Technology Transfer. Information for NIH Inventors (accessed 6 June 2023); https://www.techtransfer.nih.gov/royalty/information-nih-inventors#3
Bauchner, H. J. Am. Med. Assoc. 321, 751–752 (2019).
Bach, P. B. N. Engl. J. Med. 373, 1797–1799 (2015).
Polite, B. N., Ratain, M. J. & Lichter, A. S. JAMA Oncol 7, 25–26 (2021).
Blumenthal, D., Miller, M. E. & Gustafsson, L. Harv. Bus. Rev. (1 October 2021); https://hbr.org/2021/10/the-u-s-can-lower-drug-prices-without-sacrificing-innovation
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wesevich, A., Ratain, M.J. Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?. Nat Biotechnol 41, 1517–1519 (2023). https://doi.org/10.1038/s41587-023-02004-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-02004-2